Pricing Log in Create free account

First Tracks Biotherapeutics, Inc. (TRAX) vs Trevi Therapeutics, Inc. (TRVI)

First Tracks Biotherapeutics, Inc. and Trevi Therapeutics, Inc. are both Biotechnology companies. First Tracks Biotherapeutics, Inc. and Trevi Therapeutics, Inc. are of similar size ($1.9B and $1.8B). Across the 7 metrics below, Trevi Therapeutics, Inc. leads on 4 and First Tracks Biotherapeutics, Inc. on 3.

Valuation

Metric TRAX TRVI Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 11.31 6.93 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (10.82%) (2.39%) (32.88%)
Free cash flow yield (6.57%) (2.37%) (23.13%)

Profitability

Metric TRAX TRVI Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (19.66%) (51.96%)
Return on assets 0.00% (18.97%) (46.06%)
Return on invested capital 0.00% (1,412.11%) 0.00%

Growth

Metric TRAX TRVI Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) — 31.91% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric TRAX TRVI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.16 37.28 4.97
Net debt to EBITDA — 3.83 1.01

Dividend

Metric TRAX TRVI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric TRAX TRVI Biotechnology median
Market cap 1.91b 1.83b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack